These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9477042)

  • 1. Evaluation of haemorheological and microcirculatory disturbances in chronic venous insufficiency: activity of Daflon 500 mg.
    Le Dévéhat C; Khodabandehlou T; Vimeux M; Kempf C
    Int J Microcirc Clin Exp; 1997; 17 Suppl 1():27-33. PubMed ID: 9477042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laser Doppler and transcutaneous oximetry: modern investigations to assess drug efficacy in chronic venous insufficiency.
    Belcaro G; Cesarone MR; de Sanctis MT; Incandela L; Laurora G; Février B; Wargon C; De Gregoris P
    Int J Microcirc Clin Exp; 1995; 15 Suppl 1():45-9. PubMed ID: 8748889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From symptoms to leg edema: efficacy of Daflon 500 mg.
    Nicolaides AN
    Angiology; 2003; 54 Suppl 1():S33-44. PubMed ID: 12934755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An original microhaemorheological approach to the pharmacological effects of Daflon 500 mg in severe chronic venous insufficiency.
    Allegra C; Bartolo M; Carioti B; Cassiani D
    Int J Microcirc Clin Exp; 1995; 15 Suppl 1():50-4. PubMed ID: 8748890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical benefits of Daflon 500 mg in the most severe stages of chronic venous insufficiency.
    Ramelet AA
    Angiology; 2001 Aug; 52 Suppl 1():S49-56. PubMed ID: 11510597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HR, 0-(beta-hydroxyethyl)-rutosides, in comparison with diosmin+hesperidin in chronic venous insufficiency and venous microangiopathy: an independent, prospective, comparative registry study.
    Cesarone MR; Belcaro G; Pellegrini L; Ledda A; Di Renzo A; Vinciguerra G; Ricci A; Gizzi G; Ippolito E; Fano F; Dugall M; Acerbi G; Cacchio M
    Angiology; 2005; 56(1):1-8. PubMed ID: 15678250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy of micronized purified flavonoid fraction: an overview.
    Struckmann JR
    J Vasc Res; 1999; 36 Suppl 1():37-41. PubMed ID: 10474049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Pycnogenol and Daflon in treating chronic venous insufficiency: a prospective, controlled study.
    Cesarone MR; Belcaro G; Rohdewald P; Pellegrini L; Ledda A; Vinciguerra G; Ricci A; Gizzi G; Ippolito E; Fano F; Dugall M; Acerbi G; Cacchio M; Di Renzo A; Hosoi M; Stuard S; Corsi M
    Clin Appl Thromb Hemost; 2006 Apr; 12(2):205-12. PubMed ID: 16708123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HR (Venoruton1000, Paroven, 0-[beta-hydroxyethyl]-rutosides) vs. Daflon 500 in chronic venous disease and microangiopathy: an independent prospective, controlled, randomized trial.
    Belcaro G; Cesarone MR; Bavera P; Ricci A; Renton S; Leon M; Ippolito E; Dugall M; Acerbi G
    J Cardiovasc Pharmacol Ther; 2002 Jul; 7(3):139-45. PubMed ID: 12232562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are the phlebotonic properties shown in clinical pharmacology predictive of a therapeutic benefit in chronic venous insufficiency? Our experience with Daflon 500 mg.
    Tsouderos Y
    Int Angiol; 1989; 8(4 Suppl):53-9. PubMed ID: 2698902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advantage of a micronized flavonoidic fraction (Daflon 500 mg) in comparison with a nonmicronized diosmin.
    Amato C
    Angiology; 1994 Jun; 45(6 Pt 2):531-6. PubMed ID: 8203783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Micronized purified flavonoid fraction (MPFF): a review of its pharmacological effects, therapeutic efficacy and benefits in the management of chronic venous insufficiency.
    Katsenis K
    Curr Vasc Pharmacol; 2005 Jan; 3(1):1-9. PubMed ID: 15641940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and hemodynamic outcomes in patients with chronic venous insufficiency after oral micronized flavonoid therapy.
    Ting AC; Cheng SW; Wu LL; Cheung GC
    Vasc Surg; 2001; 35(6):443-7. PubMed ID: 16222383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venoruton vs Daflon: evaluation of effects on quality of life in chronic venous insufficiency.
    Cesarone MR; Belcaro G; Pellegrini L; Ledda A; Vinciguerra G; Ricci A; Di Renzo A; Ruffini I; Gizzi G; Ippolito E; Fano F; Dugall M; Acerbi G; Cornelli U; Hosoi M; Cacchio M
    Angiology; 2006; 57(2):131-8. PubMed ID: 16518519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of a venotropic drug in man. Example of Daflon 500 mg.
    Laurent R; Gilly R; Frileux C
    Int Angiol; 1988; 7(2 Suppl):39-43. PubMed ID: 3053942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled studies of Daflon 500 mg in chronic venous insufficiency.
    Geroulakos G; Nicolaides AN
    Angiology; 1994 Jun; 45(6 Pt 2):549-53. PubMed ID: 8203786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microcirculatory dysfunction in chronic venous insufficiency (CVI).
    Jünger M; Steins A; Hahn M; Häfner HM
    Microcirculation; 2000; 7(6 Pt 2):S3-12. PubMed ID: 11151969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three treatments for chronic venous insufficiency: escin, hydroxyethylrutoside, and Daflon.
    Frick RW
    Angiology; 2000 Mar; 51(3):197-205. PubMed ID: 10744007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vital capillaroscopy on microcirculation: pharmacodynamic activity of Daflon 500 mg in venous insufficiency.
    Balas P; Pagratis N
    Int Angiol; 1989; 8(4 Suppl):51-2. PubMed ID: 2632650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids.
    Lyseng-Williamson KA; Perry CM
    Drugs; 2003; 63(1):71-100. PubMed ID: 12487623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.